Decision to list haemodialysis products supplied by Defries Industries New Zealand Limited

Hospital devices Decision

We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with Defries Industries New Zealand Limited.

In summary this will result in:

  • Listing 12 Haemodialysis products from Defries in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018 under a national agreement that all DHBs may purchase under (“Agreement”).  Note:  the consultation incorrectly said the number of listed items was 15.

  • DHBs continuing to be able to purchase other suppliers’ brands of haemodialysis products.

This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in the Schedule 1 of the Agreement. 

Any changes to the original proposal?

This decision was subject to consultation with a letter dated 24 September 2018.

No changes have been made to the proposal following consultation.

Who we think will be most interested

  • DHB staff
    • Haemodialysis staff
    • Procurement Officers
  • Suppliers and Wholesalers

Detail about this decision

In February 2018 PHARMAC issued a Request for Proposals (“RFP”) for haemodialysis products for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After completing the RFP evaluation processes and consulting on the provisional Agreement reached with Defries, PHARMAC has decided to list Defries’ range of haemodialysis products in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018.

The list of Defries products will be available on PHARMAC's website from 1 November 2018, in both a PDF document and an Excel spreadsheet.

DHBs that purchase Defries’ haemodialysis products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 December 2018. DHBs can continue to choose which haemodialysis products they purchase.

Our response to what you told us

We appreciate the time people took to respond to this consultation. 

A summary of the main themes raised in feedback and our responses to the feedback received are set out below:


PHARMAC Staff Comment

Ministry of Health advising no technical resource impacts anticipated as a result of proposals


DHB staff requesting clarification of intended uses of custom packs

Information provided.

If you have any questions about this decision, you can email us at; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.